Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NeurAxis, Inc. ( (NRXS) ) has provided an update.
On August 29, 2025, Neuraxis, Inc. entered into an At The Market Offering Agreement with Craig-Hallum Capital Group LLC, allowing the company to sell shares of its common stock worth up to $3.3 million. This strategic move aims to provide Neuraxis with financial flexibility and potentially strengthen its market position, as the sales agent will sell the stock based on the company’s instructions, with a commission of 3% on the gross sales proceeds.
The most recent analyst rating on (NRXS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on NeurAxis, Inc. stock, see the NRXS Stock Forecast page.
Spark’s Take on NRXS Stock
According to Spark, TipRanks’ AI Analyst, NRXS is a Neutral.
NeurAxis faces significant financial challenges with negative equity and cash flow issues, which heavily impact its overall score. Despite strong revenue growth and strategic milestones, ongoing losses and valuation concerns weigh down the stock’s attractiveness.
To see Spark’s full report on NRXS stock, click here.
More about NeurAxis, Inc.
Neuraxis, Inc. operates in the biotechnology industry, focusing on the development and commercialization of innovative medical solutions.
Average Trading Volume: 92,532
Technical Sentiment Signal: Buy
Current Market Cap: $25.04M
For detailed information about NRXS stock, go to TipRanks’ Stock Analysis page.